Main Uses and Applications

Enterosgel is an intestinal adsorbent (enterosorbent) used to facilitate the removal of various exogenous and endogenous toxic substances from the gastrointestinal tract. Its primary application is focused on managing symptoms associated with digestive distress and systemic intoxication.

Acute and Chronic Diarrhea

The substance is frequently used as a symptomatic treatment for diarrhea. By binding to pathogens and their metabolic byproducts within the gut, it helps to normalize stool frequency and consistency. This application extends to:

• Acute intestinal infections (such as salmonellosis or dysentery).
• Diarrhea caused by food poisoning or viral infections.
• Chronic diarrhea associated with irritable bowel syndrome (IBS).

Detoxification and Intoxication

Enterosgel acts as a porous matrix that selectively adsorbs medium-weight molecules. It is utilized in cases of:

• Acute Poisoning: Assisting in the removal of toxic agents, including chemicals and certain medications, from the digestive system.
• Alcohol Intoxication: Helping to mitigate the effects of alcohol byproducts in the gut.
• Metabolic Waste: Aiding in the reduction of metabolic waste products, such as urea and creatinine, which may accumulate during renal or hepatic impairment.

Allergic Conditions

In the management of allergic diseases, the substance is used to reduce the systemic toxic load. It helps by binding food allergens and histamine-related compounds in the intestinal lumen, which may alleviate symptoms of:

• Atopic dermatitis.
• Urticaria (hives).
• Food intolerances.

Gastrointestinal Disorders

Beyond diarrhea, Enterosgel is used to manage general symptoms of indigestion and disturbances in the intestinal microbiota. It supports the recovery of the mucosal lining by removing substances that cause irritation or inflammation in the gut wall.

Therapeutic Benefits

Selective Adsorption

The structure of the gel allows it to target specific harmful molecules while remaining biologically inert. It does not bind to essential nutrients such as vitamins or minerals in significant quantities, nor does it interfere with the natural absorption of nutrients.

Protective Effect

By removing toxic substances and irritants, the gel helps to protect the gastrointestinal mucosa. This can reduce the duration of recovery for the intestinal lining following infection or chemical irritation.

Systemic Impact

Although Enterosgel is not absorbed into the bloodstream and acts locally within the intestine, its ability to remove toxins helps reduce the overall toxic burden on the liver and kidneys. This systemic relief is beneficial for patients with chronic conditions that involve endogenous intoxication.

Enterosgel is generally considered suitable for a wide range of individuals, including adults and children from birth, and may be used during pregnancy and breastfeeding. However, certain conditions represent contraindications where the product should not be used.

Suitable for Use

Group	Notes on Use
Adults	Suitable for symptomatic treatment of acute diarrhea and IBS-D.
Children	Recommended for use from birth, although consultation with a doctor is advisable for those under three years old.
Pregnancy/Breastfeeding	May be taken, as the substance is not absorbed into the bloodstream. Consultation with a healthcare professional is advised if the user is unwell.

---

Contraindications (Do Not Use)

Condition	Reason for Caution
Intestinal atony	Severe constipation or paralysis of the bowel.
Intestinal obstruction	Any physical blockage in the digestive tract.
Intolerance	Any known prior intolerance or hypersensitivity to Enterosgel.
Oral medications	Should be taken separately (1–2 hours before or after) to avoid affecting the absorption of other orally administered medicines, especially modified-release types.

Interactions with other medicines and products

Enterosgel (Polymethylsiloxane Polyhydrate) is a non-systemic adsorbent and does not undergo absorption, metabolism, or elimination in the body. Consequently, regulatory documents confirm that the product does not have interactions related to hepatic enzymes (CYP450) or drug transporters.

All officially documented interaction patterns are classified as physical administration-timing interferences occurring within the gastrointestinal tract. This mechanism results in a reduced systemic exposure for any co-administered substance.

Official Interaction Restrictions

Restriction Type	Interacting Substance Class	Regulatory Requirement
Contraindicated Combination	Modified-release oral medications	Must not be co-administered, as physical binding may compromise the intended time-release function.
Timing Constraint	All other oral medicines	Mandatory separation of administration by 1 to 2 hours to mitigate the risk of reduced absorption.

This principle of physical adsorption extends beyond prescription drugs to include oral supplements, herbal products, and certain food components present in the gut lumen. The core constraint documented in regulatory labeling is the prevention of physical binding with other oral substances, which necessitates strict adherence to the specified time separation.

How Enterosgel Works: The Mechanism of Selective Enterosorption

The mechanism of Enterosgel is defined by the physical process of selective enterosorption within the gastrointestinal tract; it is a non-systemic agent that operates entirely via surface interactions.

---

Physical Sequestration of Luminal Toxins

The core action of Polymethylsiloxane Polyhydrate (PMSPH) is based on selective physical adsorption within the gut. The synthetic mesoporous hydrogel functions as a molecular sieve, binding and immobilizing harmful substances, including endotoxins, bacterial enterotoxins, and certain allergens with a specific medium molecular weight range (70–1000 Da). This physical binding prevents the mobility, absorption, and interaction of these substances with the intestinal lining.

---

️ Effect on Gut Barrier Homeostasis

The core consequence of this molecular clearance is a reduction in local chemical stress on the intestinal mucosa. By clearing irritants, this action influences the environment necessary for the maintenance and restoration of the intestinal barrier function. Furthermore, this physical elimination route interrupts the enterohepatic circulation of excess endogenous metabolites (like bilirubin and urea), contributing to the reduction of endogenous toxic load in the GI tract before systemic absorption.

---

⏳ Mechanism Limitations and Selectivity

The non-systemic action is restricted by its molecular weight selectivity, meaning it does not bind significantly to very small molecules such as water, electrolytes, or beneficial nutrients, thus preserving essential body components. The binding capacity is modulated by the presence of competitive molecules and is limited by the gastrointestinal transit time necessary for the inert complex's physical excretion.

How to Use Enterosgel — Official Administration Guidelines

The following instructions reflect the general principles of use and standardized regimens.

Feature	Official Instruction
Route of administration	Oral route only, utilizing the suspension/paste form.
Dosing schedule (Adults ge 15 years)	Single Dose: 15 g to 22.5 g. Maximum Daily Dose: 60 g.
Frequency pattern	Typically administered three times per day (TID) in divided doses.
Timing in relation to meals	Must be taken 1 to 2 hours before or after a meal.
Preparation requirements	The measured dose of paste must be diluted in a specified volume of water (e.g., 200 ml for adults) or non-alcoholic liquid before ingestion.
Age-group administration rules	Pediatric dosing is tiered by age, with distinct single and total daily doses specified for children aged 1–6 years and 7–14 years.
Special procedural conditions	Administration must be separated by 2 hours from the intake of all other oral medications to prevent physical binding.
Course duration patterns	Acute use is specified as 3 to 5 days. Extended courses, such as for chronic management, may last up to 21 to 30 days, followed by a required break before any repeat cycle.

---

The official administration protocol is structured around three key administrative principles: the oral delivery of a pre-measured, diluted dose; mandatory time separation from food and other oral medicines; and adherence to standardized, age-specific dosing schedules. This framework establishes the procedure for administering the non-systemic product, ensuring that the usage pattern aligns with standardized health protocols.

Evidence for Use in Acute Diarrhea

Research on Enterosgel (Polymethylsiloxane Polyhydrate) was studied for use in conditions associated with acute diarrhea. Studies primarily used short-term Randomized Controlled Trials (RCTs) in both adult and pediatric populations, examining time-based measurements such as the duration of diarrhea and time to recovery. Research explored the reported duration of diarrhea when the product was administered alongside standard care. However, these findings come with certain research limitations, including the lack of a true inert placebo control in some studies and limited long-term follow-up beyond the acute episode.

---

Evidence for Use in Irritable Bowel Syndrome with Diarrhea (IBS-D)

For managing symptoms of Irritable Bowel Syndrome with Diarrhea (IBS-D), the evidence base includes large-scale, double-blinded, placebo-controlled, multi-centre RCTs focused on adults. These studies monitored outcomes related to physical discomfort and daily functioning. Researchers primarily focused on a composite responder endpoint, measuring concurrent changes in both abdominal pain severity and stool consistency. Findings describe patterns in this composite endpoint observed in the group receiving the product. Older data sets, however, lacked placebo controls, which is a research limitation across the full history of the study.

---

Duration, Special Populations, and Uncertainty

The research provides context for two time frames: short-term for acute diarrhea and an intermediate period (up to 26 weeks) for the IBS-D trials. Studies specifically focused on children presenting with acute gastroenteritis, but the core evidence for IBS-D was focused on adults. Data for certain groups remain insufficient, as the main controlled trials did not focus on other specific special populations. Overall, long-term effects and the durability of observed outcomes are not fully established by the existing research.

Key Studies & References Polymethylsiloxane polyhydrate - PubChem Substance Record

Common questions about Enterosgel (FAQ)

Q: What is the main difference between Enterosgel and activated charcoal?

Regulatory information indicates that the product's action is defined by selective enterosorption, meaning it is designed to bind substances within a specific medium molecular weight range in the gut. Official sources note the importance of informing a health professional about the use of other intestinal adsorbents, such as those containing activated charcoal, clay, or kaolin, when using this product.

Q: Is Enterosgel classified as a medicine, a medical device, or a supplement in different countries?

The product is often identified as a Class IIa Medical Device in jurisdictions like the European Union and the United Kingdom. This designation reflects its non-absorbed, physical action within the digestive tract.

Q: How does Enterosgel compare to other popular anti-diarrhea medications?

The official product description highlights that it is a non-systemic agent, which means it is not absorbed, metabolized, or eliminated by the body. This non-systemic, physical action of binding substances in the gut lumen is noted in regulatory descriptions as a distinguishing feature from traditional anti-diarrhea medications, which often operate via systemic effects.

Q: Is it necessary to drink extra water when using Enterosgel?

The official product instructions describe a requirement that the measured dose of paste is diluted in a specified amount of water or non-alcoholic liquid prior to administration. Furthermore, adequate fluid intake is generally recommended during the treatment of acute diarrhea.

Q: What do official documents say about the maximum period a person should take Enterosgel?

Regulatory documents describe the typical duration of treatment as 3 to 5 days for acute diarrhea. For chronic conditions like IBS-D, treatment periods are described as being able to extend up to 21 or 30 days, followed by a required break before any new cycle.

Q: Do you need a prescription from a doctor to buy Enterosgel?

The product is widely described in official sources as being available over-the-counter (OTC), meaning it can be purchased without a prescription. While it is generally not a prescription-only product, it may be covered by prescription in some specific local territories.

Q: Can people with sensitive stomachs or chronic digestive issues use Enterosgel?

Official information states that the product is indicated for the symptomatic treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D), which is considered a chronic digestive condition. However, it is important to note that contraindications include existing severe constipation, called intestinal atony, or any physical intestinal obstruction.

Q: Does Enterosgel have a taste, and what does the packaging say about it?

Official product information, such as patient leaflets, describes the product as being flavourless or tasteless. It is also stated to be free of added flavourings, sugars, and preservatives.

Q: Can Enterosgel be mixed with any liquids other than water?

The official product instructions indicate that the dose should be diluted in water or a non-alcoholic liquid of room temperature prior to being taken.

Q: Is it true that Enterosgel can help with allergy symptoms?

The product's mechanism of action is described in official sources as binding and removing certain allergens from the gut lumen. However, its primary regulated indications for use focus on the symptomatic treatment of acute diarrhea and IBS-D.

Q: Is Enterosgel ever used in hospitals or clinical settings?

Records from clinical trial registries confirm that the product has been investigated in hospital sites and secondary care centres. This reflects its inclusion in structured clinical research settings.

Q: Is Enterosgel gluten-free, sugar-free, or free of common allergens?

According to official patient information, the product is free of a number of common dietary components. It is explicitly stated to be sugar-free, sweetener-free, lactose-free, gluten-free, fat-free, colour-free, flavour-free, and preservative-free.

Q: Does Enterosgel interact with alcohol or caffeine?

Official instructions require that the product be diluted in a non-alcoholic liquid and confirm that the product itself does not contain alcohol. Since the product's action is physical, the standard regulatory rule applies: administration should be separated from all other oral substances.

Q: Is Enterosgel used for detox purposes or cleansing, and what is the official stance?

The product is classified in some contexts as a Detoxifying Agent, and its purpose is described as cleansing the digestive tract to achieve a reduction of toxin load. This aligns with its physical mechanism of binding and removing harmful substances from the gut.

Q: What happens if you accidentally use more Enterosgel than recommended in the instructions?

The official patient information includes a statement that the recommended dose should not be exceeded. Furthermore, regulatory information states that the product is not indicated for use in cases of acute chemical poisoning or medicinal overdose.

Q: What is the difference in use between the tube and the sachets, if any?

The difference is primarily related to stability and packaging. The sachets are designed for single use only and must be used immediately upon opening. Conversely, the tube must be closed tightly after use and the remaining product must be used within 30 days of initial opening.

Q: Can Enterosgel be used during periods of vomiting as well as diarrhea?

The product's stated indications for use are focused on diarrhea. Official safety notes include a strong warning that medical attention should be sought immediately if a person experiences diarrhea and vomiting at the same time, especially in children, or if frequent vomiting occurs.

Storage and Disposal of Enterosgel®

Official regulatory documents define the required conditions for storing Enterosgel® (Polymethylsiloxane Polyhydrate) to maintain its integrity and stability.

Required Storage Conditions

Condition	Requirement
Temperature Range	Store between 4 C and 30 C.
Prohibited Conditions	Do not freeze the product. Protect from direct sunlight and heat.
Child Safety	Keep out of the sight and reach of children.

Stability and Container Rules

For the oral suspension in a tube, the lid must be closed tightly after each use, and the product must be used within 30 days after opening. Sachets are for single use only. The product must not be used after the stated expiry date.

Disposal Instructions

There are no special disposal requirements for unused or expired Enterosgel®. The product can be safely disposed of into the domestic waste. The packaging itself can be recycled.